Rare blood clot disorder among people who received J&J vaccine
In what can be a major relief to millions, especially two major vaccine manufacturers, Oxford/AstraZeneca and Johnson & Johnson, scientists in Germany claim they might have just cracked the rare blood clots linked to their jabs. The research, led by Rolf Marschalek, a professor at Goethe University in Frankfurt, into the rare condition was started back in March and now scientists are able to explain the underlying cause behind the blood clots people have suffered after getting inoculated. With this, the scientists are confident that with the right modifications, the side effect, proven to be deadly in some cases, can finally be fixed.
German scientist believes he s found solution to blood clots linked to AstraZeneca, Johnson & Johnson COVID-19 vaccines theweek.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theweek.com Daily Mail and Mail on Sunday newspapers.
Express News Service
NEW DELHI: The 2DG (2-Deoxy-D-glucose) drug will be equally effective on corona patients, believes Professor Dr Vinay Jain, former director of the Institute of Nuclear Medicine & Allied Sciences (INMAS), who played an instrumental role in introducing the drug in India for the treatment of brain cancer patients. 2DG has been given nod by authorities for treating Covid-19 patients.
“The metabolism of both tumour and Covid-infected cells is almost the same. Once the virus enters the cell, it replicates itself and uses a cell machiner. It is the same as what a tumour does in the human body. The energy requirement of the Covid virus is much similar to how the tumour functions. Hence, the drug will play a crucial role in treating corona patients,” Dr Jain said.He further noted that the drug has the potential to resist entry of the coronavirus into the body, though more verification is needed on that aspect.